Genentech at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
Genentech takes part in 4 sessions at Antibody Engineering 2026 in San Diego. Its sessions cover how antibody-based protein degraders work and new animal-based ways to find antibodies against hard targets. One uses lipid nanoparticle mRNA, an approach carried over from COVID to cancer, as the antigen for finding antibodies against difficult membrane proteins.
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines. | Talk Sun Dec 13 11:00am–11:45am Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Talk Tue Dec 15 8:10am–8:15am Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering |
Instantly find 20 buyers from Genentech
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction